To the Editor In an article published in a recent issue of JAMA Internal Medicine, Luo et al1 fail to accurately characterize trends in prices for diabetes medicines in Medicaid by inaccurately suggesting that statutory rebates are capped at 23.1%, and such discounts could not be large enough to offset list price increases. In fact, Medicaid receives, on average, about a 60% discount2 because the 23.1% rebate the authors cite is a minimum, not a maximum; this is because Medicaid is guaranteed the best price on the commercial market and individual states often negotiate additional discounts.
Bryant J. Inaccurate Reporting of Insulin Reimbursement. JAMA Intern Med. 2016;176(3):408. doi:10.1001/jamainternmed.2015.8098